Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast

The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.), Zejula (GlaxoSmithKline), and Rubraca (Clovis Oncology). In November 2022, Elahere (ImmunoGen) entered the U.S. market as the first antibody-drug conjugate for patients with folate receptor alpha (FRα)-positive tumors. The late-phase pipeline for ovarian cancer is rapidly evolving. Novel drugs with a variety of mechanisms of action are set to launch for ovarian cancer and further diversify treatment options.

Questions answered

  • What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?
  • What is the current treatment landscape for ovarian cancer? What are interviewed experts’ insights on current therapies?
  • What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?
  • What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Table of contents

  • Ovarian Cancer - Landscape & Forecast - Disease Landscape & Forecast
    • Key Findings
      • Key Updates
        • August 2023
        • May 2023
        • April 2023
        • Q4 2022
          • December 2022
          • November 2022
      • Market Outlook
        • Key findings
          • Market share of drug classes for ovarian cancer: 2022
          • Market share of drug classes for ovarian cancer: 2032
          • Drug-treatable population share and major-market sales share in ovarian cancer: 2022
          • Drug-treatable population share and major-market sales share in ovarian cancer: 2032
          • Population positioning of therapies in ovarian cancer: United States
          • Population positioning of therapies in ovarian cancer: Europe
          • Population positioning of therapies in ovarian cancer: Japan
          • Ovarian cancer SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for ovarian cancer?
          • What factors are constraining the market for ovarian cancer?
          • Major-market sales for ovarian cancer by region: 2022-2032
          • Major-market sales for ovarian cancer by drug class: 2022-2032
          • Major-market sales of targeted therapies in the ovarian cancer market: 2022-2032
          • Major-market sales of PARP inhibitors by patient population: 2022-2032
        • Segment-specific trends
          • Patient-share dynamics of key therapies (excluding maintenance) in first-line advanced-stage ovarian cancer in the United States: 2022-2032
          • Patient-share dynamics of maintenance therapies in first-line advanced-stage ovarian cancer in the United States: 2022-2032
          • Patient-share dynamics of key therapies excluding maintenance treatments in the second-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
          • Patient-share dynamics of maintenance therapies in the second-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
          • Patient-share dynamics of key therapies excluding maintenance treatments in the third-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
          • Patient-share dynamics of maintenance therapies in the third-line platinum-sensitive ovarian cancer setting in the United States: 2022-2032
          • Patient-share dynamics of second-line platinum-resistant and platinum-refractory ovarian cancer in the United States: 2022-2032
          • Patient-share dynamics of third-line platinum-resistant and platinum-refractory ovarian cancer in the United States: 2022-2032
          • Patient-share dynamics of key therapies in the fourth- and subsequent-line ovarian cancer setting in the United States: 2022-2032
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease overview
          • Disease pathophysiology
            • Disease pathogenesis
            • Disease classification
            • Ovarian cancer histologies
            • Molecular subtypes and key pathways
            • Screening tests: CA-125
          • Staging and classification
            • Staging and grading
            • International Federation of Gynecology and Obstetrics staging system for cancer of the ovary, fallopian tube, and peritoneum
            • Stage I-II
            • Stage III-IV
          • Key pathways and drug targets
            • Key pathways and drug targets in ovarian cancer
            • Key signaling pathways in epithelial cells
            • PARP inhibition: mechanism of action
            • Folate receptor pathway
            • Immune checkpoint inhibitors and modulators
        • Epidemiology
          • Key findings
            • Epidemiology populations
              • Disease definition, methods, and sources used
              • Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancers: 2022-2032
              • Disease definition, methods, and sources used
              • Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer by stage: 2022-2032
              • Disease definition, methods, and sources used
              • Diagnosed incident cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer by BRCA mutation: 2022-2032
              • Disease definition, methods, and sources used
              • Recurrent incident cases of epithelial ovarian and fallopian tube cancer: 2022-2032
              • Ovarian cancer patient flow
              • Drug-treatable cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer: 2022-2032
              • Drug-treated cases of epithelial ovarian, fallopian tube, and primary peritoneal cancer: 2022-2032
          • Current Treatment
            • Key findings
              • Treatment goals
                • Key endpoints used in clinical trials for ovarian cancer
              • Key current therapies
                • Overview
                • Mechanism of action of key current drug classes used for ovarian cancer
                • Current treatments used for ovarian cancer
                • Market events impacting the use of key current therapies in ovarian cancer
                • Key results from select clinical trials investigating bevacizumab for the treatment of ovarian cancer
                • Ongoing clinical development of bevacizumab
                • Expert insight: bevacizumab
                • Key results from select clinical trials investigating Lynparza for the treatment of ovarian cancer
                • Ongoing clinical development of Lynparza
                • Key ongoing clinical trials of Lynparza in the treatment of ovarian cancer
                • Expert insight: Lynparza
                • Key results from select clinical trials investigating Rubraca for the treatment of ovarian cancer
                • Ongoing clinical development of Rubraca
                • Key ongoing clinical trials investigating Rubraca in the treatment of ovarian cancer
                • Expert insight: Rubraca
                • Key results from select clinical trials investigating Zejula for the treatment of ovarian cancer
                • Ongoing clinical development of Zejula
                • Key ongoing clinical trials investigating Zejula in the treatment of ovarian cancer
                • Expert insight: Zejula
                • Key results of select clinical trials investigating Elahere for the treatment of ovarian cancer
                • Ongoing clinical development of Elahere
                • Key ongoing clinical trials of Elahere in the treatment of ovarian cancer
                • Expert insight: Elahere
                • Key results from select clinical trials investigating Yondelis for the treatment of ovarian cancer
                • Ongoing clinical development of Yondelis
                • Key results of select clinical trials investigating Mekinist for the treatment of ovarian cancer
                • Ongoing clinical development of Mekinist
                • Expert insight: Mekinist
              • Medical practice
                • Early-stage first-line ovarian cancer
                • Advanced-stage first-line ovarian cancer
                • Second- and third-line platinum-sensitive ovarian cancer
                • Second- and third-line platinum-resistant and -refractory ovarian cancer
                • Fourth- and subsequent-line ovarian cancer
                • Country-specific ovarian cancer treatment guidelines
                • Patient characteristics influencing drug selection in ovarian cancer
                • Treatment decision tree for early- and advanced-stage ovarian cancer: United States
                • Treatment decision tree for early- and advanced-stage ovarian cancer: Europe
                • Treatment decision tree for early- and advanced-stage ovarian cancer: Japan
            • Unmet Need Overview
              • Current and future attainment of unmet needs in ovarian cancer
              • Top unmet needs in ovarian cancer: current and future attainment
            • Drug Pipeline
              • Pipeline
              • Regulatory Milestones
              • Indication Comparison
            • Emerging Therapies
              • Key findings
                • Key emerging therapies
                  • Key therapies in development for ovarian cancer
                  • Estimated market authorization dates of key emerging therapies for the treatment of ovarian cancer
                  • Key results of select clinical trials investigating Tecentriq for the treatment of ovarian cancer
                  • Key ongoing clinical trials of Tecentriq in the treatment of ovarian cancer
                  • Analysis of the clinical development program for Tecentriq
                  • Expert insight: Tecentriq
                  • Expectations for market authorization and sales opportunity of Tecentriq in ovarian cancer
                  • Key results of select clinical trials investigating Keytruda for the treatment of ovarian cancer
                  • Key ongoing clinical trials of Keytruda in the treatment of ovarian cancer
                  • Analysis of the clinical development program for Keytruda
                  • Expert insight: Keytruda
                  • Expectations for market authorization and sales opportunity of Keytruda in ovarian cancer
                  • Key results of select clinical trials investigating Opdivo for the treatment of ovarian cancer
                  • Key ongoing clinical trials of Opdivo in the treatment of ovarian cancer
                  • Analysis of the clinical development program for Opdivo
                  • Expert insight: Opdivo
                  • Expectations for market authorization and sales opportunity of Opdivo in ovarian cancer
                  • Key results of select clinical trials investigating Imfinzi for the treatment of ovarian cancer
                  • Analysis of the clinical development program for Imfinzi
                  • Expert insight: Imfinzi
                  • Expectations for market authorization and sales opportunity of Imfinzi in ovarian cancer
                  • Key results of select clinical trials investigating Jemperli for the treatment of ovarian cancer
                  • Key ongoing clinical trials of Jemperli in the treatment of ovarian cancer
                  • Analysis of the clinical development program for Jemperli
                  • Expert insight: Jemperli
                  • Expectations for market authorization and sales opportunity of Jemperli in ovarian cancer
                  • Key results of select clinical trials investigating olvimulogene nanivacirepvec for the treatment of ovarian cancer
                  • Key ongoing clinical trials of olvimulogene nanivacirepvec in the treatment of ovarian cancer
                  • Analysis of the clinical development program for olvimulogene nanivacirepvec
                  • Expectations for market authorization and sales opportunity of olvimulogene nanivacirepvec in ovarian cancer
                  • Key results of select clinical trials investigating relacorilant for the treatment of ovarian cancer
                  • Key ongoing clinical trials of relacorilant in the treatment of ovarian cancer
                  • Analysis of the clinical development program for relacorilant
                  • Expert insight: relacorilant
                  • Expectations for market authorization and sales opportunity of relacorilant in ovarian cancer
                  • Key results of select clinical trials investigating oregovomab for the treatment of ovarian cancer
                  • Key ongoing clinical trials of oregovomab in the treatment of ovarian cancer
                  • Analysis of the clinical development program for oregovomab
                  • Expert insight: oregovomab
                  • Expectations for market authorization and sales opportunity of oregovomab in ovarian cancer
                  • Key results of select clinical trials investigating Piqray for the treatment of ovarian cancer
                  • Key ongoing clinical trials of Piqray in the treatment of ovarian cancer
                  • Analysis of the clinical development program for Piqray
                  • Expert insight: Piqray
                  • Expectations for market authorization and sales opportunity of Piqray in ovarian cancer
                  • Key results of select clinical trials investigating batiraxcept for the treatment of ovarian cancer
                  • Analysis of the clinical development program for batiraxcept
                  • Expert insight: batiraxcept
                  • Expectations for market authorization and sales opportunity of batiraxcept in ovarian cancer
                  • Key ongoing clinical trials of nemvaleukin alfa in the treatment of ovarian cancer
                  • Analysis of the clinical development program for nemvaleukin alfa
                  • Expert insight: nemvaleukin alfa
                  • Expectations for market authorization and sales opportunity of nemvaleukin alfa in ovarian cancer
                  • Key results of select clinical trials investigating upifitamab rilsodotin for the treatment of ovarian cancer
                  • Key ongoing clinical trials of upifitamab rilsodotin in the treatment of ovarian cancer
                  • Analysis of the clinical development program for upifitamab rilsodotin
                  • Expert insight: upifitamab rilsodotin
                  • Expectations for market authorization and sales opportunity of upifitamab rilsodotin in ovarian cancer
                  • Key results of select clinical trials investigating navicixizumab for the treatment of ovarian cancer
                  • Key ongoing clinical trials of navicixizumab in the treatment of ovarian cancer
                  • Analysis of the clinical development program for navicixizumab
                  • Expert insight: navicixizumab
                  • Expectations for market authorization and sales opportunity of navicixizumab in ovarian cancer
                • Early-phase pipeline analysis
                  • Select compounds in Phase 1/2 development for ovarian cancer
              • Access and Reimbursement Overview
                • Region-specific reimbursement practices
                  • Key market access considerations in ovarian cancer: United States
                  • General reimbursement environment: United States
                  • Key market access considerations in ovarian cancer: EU5
                  • General reimbursement environment: EU5
                  • Key market access considerations in ovarian cancer: Japan
                  • General reimbursement environment: Japan
              • Appendix
                • Ovarian cancer bibliography

            Login to access report